Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status  Phase of research How it helps Latest publication
EpiVacCorona
Approved (Russia) Experimental Vaccine Oct/15/2020
Remdesivir
Approved by FDA Experimental Antiviral Jan/18/2023
BNT162b2
Approved by FDA Experimental Vaccine Jun/22/2022
N-[(1R)-2-[4-(1-Methylpiperidin-4-yl)piperazin-1-yl]-2-oxo-1-phenylethyl]-1H-indole-6-carboxamide
Approved for COVID-19 treatment (China, India, Russia) Experimental Antiviral Sep/18/2020
Regdanvimab
Authorized Experimental Antiviral
Convalescent plasma
Emergency use authorization Experimental Antiviral May/16/2022
Cilgavimab
Emergency use authorization Experimental Antiviral Jun/18/2022
Ad26.COV2.S
Emergency use authorization Experimental Vaccine Jun/22/2022
Nirmatrelvir
Emergency use authorization Experimental Antiviral Jun/23/2022
ZyCoV-D
Emergency use authorization Experimental Vaccine Mar/26/2020
Molnupiravir
Emergency use authorization Experimental Antiviral Jun/23/2022
Tixagevimab
Emergency use authorization Experimental Antiviral Jun/18/2022
BBV152
Emergency use authorization Experimental Vaccine Mar/27/2021
mRNA-1273
Emergency use authorization Experimental Vaccine Jun/22/2022
Gam-COVID-Vac
Emergency use authorization Experimental Vaccine Dec/23/2021
ChAdOx1 nCoV-19
Emergency use authorization Experimental Vaccine Jan/04/2022
Sotrovimab
Emergency use authorization Experimental Antiviral Jul/14/2022
REGEN-COV
Emergency use authorization Experimental Antiviral Jun/03/2022
Bebtelovimab
Emergency use authorization Experimental Antiviral Jun/18/2022
Casirivimab
Emergency use authorization Experimental Antiviral Jan/23/2023